Global Cord Blood (NYSE:CO) Earns Strong-Buy Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Global Cord Blood (NYSE:CO) in a report released on Saturday morning. The brokerage issued a strong-buy rating on the medical research company’s stock.

Global Cord Blood Stock Performance

NYSE CO opened at $1.25 on Friday. The stock has a market capitalization of $151.94 million, a price-to-earnings ratio of 1.95 and a beta of 0.16. Global Cord Blood has a twelve month low of $2.03 and a twelve month high of $5.50. The stock has a 50-day moving average of $1.51 and a 200 day moving average of $1.36.

About Global Cord Blood

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.